Supplementary data

Biomarkers for atopic dermatitis: a systematic review & meta-analysis

Judith Thijs MD1; TodorKrastev MD1; Stephan Weidinger MD, PhD2;Constantinus F Buckens MD3; Marjolein de Bruin-Weller MD, PhD1; Carla Bruijnzeel-Koomen MD, PhD1; Carsten Flohr MD, PhD4;DirkJan Hijnen MD, PhD1

  1. Department of Dermatology and Allergy, University Medical Center Utrecht, Utrecht, The Netherlands
  2. Department of Dermatology, Venereology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Germany
  3. Department of Radiology, University Medical Center Utrecht, Utrecht, The Netherlands
  4. Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' Hospitals NHS Foundation Trust and King's College, London, United Kingdom.

Corresponding author:

DirkJan Hijnen, MD, PhD

Department of Dermatology and Allergy

University Medical Center Utrecht

Heidelberglaan 100, Room G02.124

3584CX Utrecht

The Netherlands

Table S1. Data extraction

Longitudinal studies

Multiple measurements (mostly values before and after treatment)

  • study size (number of patients)
  • mean/median age of AD patients
  • AD severity scoring system (SCORAD, SASSAD, EASI, LSS)
  • mean length of follow-up (days)
  • significant or non-significant changes in biomarker values and severity scores
  • r-value (Spearman/Pearson correlation coefficient)

Cross-sectional studies

Single measurements in AD patients

  • study size (number of patients)
  • significant or non-significant correlation biomarker-scoring system?
  • r-value (Spearman/Pearson correlation coefficient)

Outcome measurements

Correlation between: change in biomarker and change in clinical severity score

Table S2. Biomarkers

Biomarker / References / Biomarker / References
OxLDL / 1 / sIgA / 107,108,109,110
p5-HT / 2 / sIgE / 6,8,9,13,14,15,18,19,22,28,30,31,34,36,37,38,40,43,44,45,46,48,50,55,56,58,59,60,63,64,66,67,85,86,88,89,94,98, 104,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169
pBDNF / 3 / sIgFLC / 146
pB-TG / 4 / sIgG / 107,108,109,110
pCD26 / 5 / sIgM / 107,109
pCD30 / 5 / sIL-10 / 50,107,129,131,135,155,170,171
pCGRP / 6,7 / sIL-13 / 131,172
pCTACK / 3,8,9 / sIL-16 / 46,84,104,153,173
pEDN / 10 / sIL-18 / 87,129,135,141,158,174,175
pEotaxin / 11 / sIL-1ra / 49
pE-selectin / 12 / sIL-2R / 29,35,37,38,46,60,63,69,73,76,102,120,129,176,177
pICAM-1 / 12 / sIL-2sRa / 49
pIFN-y / 13 / sIL-31 / 178,179,180,181,182,183
pIL-12 / 13 / sIL-4 / 30,36,37,50,90,116,131,154,155,171,172,184,185
pIL-18 / 13,14 / sIL-4R / 73
pIL-1b / 15,16 / sIL-5 / 89,90,95,172,185
pIL-6 / 15 / sIL-6 / 29,154,155
pIL-8 / 15 / sIL-8 / 96
pMDC / 11,13 / sIL-9 / 186,187
pMMP-9 / 17 / sINF-y / 107,185
pNGF / 7 / sIP-10 / 96
pNPY / 6,7 / sI-TAC / 96
pPDMP / 18 / sLDH / 13,117,140,148,158,162,167,169,179,188
pPF4 / 4 / sLDH5 / 128
p-sPselectin / 18 / sLL-37 / 189
psubstance-P / 6,9 / sMBP / 97a,190
pTARC / 3,8,9, 11 ,13,19 / sMCP-1 / 96
pTM / 20 / sMCP-1a / 49
pVCAM-1 / 12 / sMDC / 55,57,84,93,94,96,102,104,144,191,192
pVEGF / 21 / sMIG / 96
sApelin / 22 / sMIP1-a / 96
sApril / 23,24 / sMIP1-b / 96
sATX / 25 / sNGF / 27,172,193,194,195,196
sBAFF / 23 / sNitrate / 197
sBDNF / 26,27 / sNPY / 172
sB-endorphin / 28 / sOX40L / 170
sCD14 / 29,30,31,32,33 / sPAFAH activity / 14
sCD23 / 29,33,34,35,36,37,38 / sPeriostin / 169
sCD25 / 33 / sRANTES / 49,96
sCD26 / 39 / sResistin / 22
sCD30 / 33,37,38,40,41,42,43,44,45,46,47,48, / sSCCA / 198
sCD4 / 49 / sSEA-IgE / 123,199,200
sCD5 / 50 / ssKIT / 51
sCD8 / 49 / sSubstance-P / 193,195,201
sCSF / 51 / sTARC / 53,55,56,57,58,94,96,101,144,145,158,162,165,167,169,170,182,188,191,192,202,203,204,205,206,207,208,209,210
sCTACK / 52,53,54,55,56,57,58 / sTGF-B1 / 49
sECP / 26,29,30,35,43,45,55,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92 / sTNF-a / 49,171,211
sEDN / 10 / sTryptase / 143
sELAM-1 / 66,69,76 / sTSLP / 170,212
sEotaxin / 46,93,94,95,96 / sVAP-1 / 213
sEPX / 79,80 / sVCAM-1 / 82,98,103
sE-selectin / 26,30,82,84,97,98,99,100,101,102,103,104 / sVE-cadherin / 214
sGM-CSF / 49 / sVIP / 28,215
sGROa / 96 / sVisfatin / 22
sICAM-1 / 49,64,66,69,76,98,99,103 / sVitD / 160,216,217,218,219,220,221,222
sMEC / 105,106

Figure S1. Funnel plots of longitudinal studies

TARC
/ sE-selectin

Total IgE
/ ECP

Figure S2. Funnel plots of cross-sectional studies

TARC
/ MDC

CTACK
/ IL-18

LDH
/ IgE

ECP
/ CD30

Vitamin D

References

1.Kaur, S.; Kullisaar, T.; Mikelsaar, M.; Eisen, M.; Rehema, A.; Vihalemm, T.; Zilmer, K.; Zilmer, M. Successful management of mild atopic dermatitis in adults with probiotics and emollients Central European Journal of Medicine [Online], 2008, p. 215-20.

2.Soga, F.; Katoh, N.; Inoue, T.; Kishimoto, S., Serotonin activates human monocytes and prevents apoptosis. J Invest Dermatol 2007, 127 (8), 1947-55.

3.Hon, K. L.; Lam, M. C.; Wong, K. Y.; Leung, T. F.; Ng, P. C., Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P. The British journal of dermatology 2007, 157 (5).

4.Tamagawa-Mineoka, R.; Katoh, N.; Ueda, E.; Masuda, K.; Kishimoto, S., Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of beta-thromboglobulin and platelet factor 4. Allergol Int 2008, 57 (4), 391-6.

5.Katoh, N.; Hirano, S.; Suehiro, M.; Ikenaga, K.; Yamashita, T.; Sugawara, N.; Yasuno, H., Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26. Clinical and experimental immunology 2000, 121 (2).

6.Salomon, J.; Baran, E., The role of selected neuropeptides in pathogenesis of atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV 2008, 22 (2).

7.Latief; El-Bendary, A.; Abu-Raya, A.; Hodeib, A., Nerve growth factor, neuropeptides and cutaneous nerves in atopic dermatitis. Indian journal of dermatology 2010, 55 (2).

8.Nakamura, K., IgE and TARC (thymus and activation regulated chemokine) as diagnostic markers for the evaluation of severity of atopic dermatitis. Skin Research 2005, 4 (SUPPL. 5).

9.Hon, K. L.; Lam, M. C.; Leung, T. F.; Wong, K. Y.; Chow, C. M.; Fok, T. F.; Ng, P. C., Are age-specific high serum IgE levels associated with worse symptomatology in children with atopic dermatitis? International journal of dermatology 2007, 46 (12).

10.Morioka, J.; Tomita, M.; Yoshizawa, Y.; Inamura, H.; Kurosawa, M., Concentrations of eosinophil-derived neurotoxin in the blood and urine of patients with allergic diseases. Allergology International 2004, 53 (4), 359-367.

11.Fujisawa, T.; Fujisawa, R.; Kato, Y.; Nakayama, T.; Morita, A.; Katsumata, H.; Nishimori, H.; Iguchi, K.; Kamiya, H.; Gray, P. W.; Chantry, D.; Suzuki, R.; Yoshie, O., Presence of high contents of thymus and activation-regulated chemokine in platelets and elevated plasma levels of thymus and activation-regulated chemokine and macrophage-derived chemokine in patients with atopic dermatitis. The Journal of allergy and clinical immunology 2002, 110 (1).

12.Wolkerstorfer, A.; Laan, M. P.; Savelkoul, H. F.; Neijens, H. J.; Mulder, P. G.; Oudesluys-Murphy, A. M.; Sukhai, R. N.; Oranje, A. P., Soluble E-selectin, other markers of inflammation and disease severity in children with atopic dermatitis. The British journal of dermatology 1998, 138 (3).

13.Furukawa, H.; Takahashi, M.; Nakamura, K.; Kaneko, F., Effect of an antiallergic drug (Olopatadine hydrochloride) on TARC/CCL17 and MDC/CCL22 production by PBMCs from patients with atopic dermatitis. Journal of dermatological science 2004, 36 (3).

14.Ohnishi, H.; Kato, Z.; Watanabe, M.; Fukutomi, O.; Inoue, R.; Teramoto, T.; Kondo, N., Interleukin-18 is associated with the severity of atopic dermatitis. Allergology International 2003, 52 (3).

15.Kimata, H.; Lindley, I. Detection of plasma interleukin-8 in atopic dermatitis Archives of Disease in Childhood [Online], 1994, p. 119-22.

16.Nutan, F. N.; Kanwar, A. J.; Parsad, D., The effect of topically applied corticosteroids on interleukin 1beta levels in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2012, 26 (8), 1020-2.

17.Devillers, A. C.; van Toorenenbergen, A. W.; Klein Heerenbrink, G. J.; Muldert, P. G.; Oranje, A. P., Elevated levels of plasma matrix metalloproteinase-9 in patients with atopic dermatitis: a pilot study. Clin Exp Dermatol 2007, 32 (3), 311-3.

18.Tamagawa-Mineoka, R.; Katoh, N.; Ueda, E.; Masuda, K.; Kishimoto, S., Platelet-derived microparticles and soluble P-selectin as platelet activation markers in patients with atopic dermatitis. Clin Immunol 2009, 131 (3), 495-500.

19.Yoshida, Y.; Seki, T.; Matsunaka, H.; Watanabe, T.; Shindo, M.; Yamada, N.; Yamamoto, O., Clinical effects of probiotic bifidobacterium breve supplementation in adult patients with atopic dermatitis. Yonago acta medica 2010, 53 (2).

20.Yoshijima, S.; Kojima, T.; Sasai, M.; Hattori, K.; Taniuchi, S.; Kobayashi, Y., Plasma thrombomodulin levels in children with atopic dermatitis. Acta Paediatr 2001, 90 (2), 130-2.

21.Koczy-Baron, E.; Jochem, J.; Kasperska-Zajac, A., Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activation. Inflamm Res 2012, 61 (12), 1405-9.

22.Machura, E.; Szczepanska, M.; Ziora, K.; Ziora, D.; Swietochowska, E.; Barc-Czarnecka, M.; Kasperska-Zajac, A., Evaluation of adipokines: apelin, visfatin, and resistin in children with atopic dermatitis. Mediators Inflamm 2013, 2013, 760691.

23.Matsushita, T.; Fujimoto, M.; Echigo, T.; Matsushita, Y.; Shimada, Y.; Hasegawa, M.; Takehara, K.; Sato, S., Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis. Exp Dermatol 2008, 17 (3), 197-202.

24.Ibrahim, Z. A.; Ghaly, N. R.; El-Tatawy, R. A.; Khalil, S. M.; El-Batch, M. M., A proliferation-inducing ligand in atopic dermatitis and vitiligo. International Journal of Dermatology 2014, 53 (9), 1073-1079.

25.Nakao, M.; Sugaya, M.; Suga, H.; Kawaguchi, M.; Morimura, S.; Kai, H.; Ohmatsu, H.; Fujita, H.; Asano, Y.; Tada, Y.; Kadono, T.; Sato, S., Serum autotaxin levels correlate with pruritus in patients with atopic dermatitis. J Invest Dermatol 2014, 134 (6), 1745-7.

26.Namura, K.; Hasegawa, G.; Egawa, M.; Matsumoto, T.; Kobayashi, R.; Yano, T.; Katoh, N.; Kishimoto, S.; Ohta, M.; Obayashi, H.; Ose, H.; Fukui, M.; Nakamura, N.; Yoshikawa, T., Relationship of serum brain-derived neurotrophic factor level with other markers of disease severity in patients with atopic dermatitis. Clinical immunology (Orlando, Fla.) 2007, 122 (2).

27.Raap, U.; Werfel, T.; Goltz, C.; Deneka, N.; Langer, K.; Bruder, M.; Kapp, A.; Schmid-Ott, G.; Wedi, B., Circulating levels of brain-derived neurotrophic factor correlate with disease severity in the intrinsic type of atopic dermatitis. Allergy 2006, 61 (12).

28.Lee, C. H.; Chuang, H. Y.; Shih, C. C.; Jong, S. B.; Chang, C. H.; Yu, H. S., Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. Br J Dermatol 2006, 154 (6), 1100-7.

29.Wuthrich, B.; Kagi, M. K.; Joller-Jemelka, H., Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis. Archives of Dermatological Research 1992, 284 (6).

30.Furue, M.; Koga, T.; Yamashita, N., Soluble E-selectin and eosinophil cationic protein are distinct serum markers that differentially represent clinical features of atopic dermatitis. The British journal of dermatology 1999, 140 (1).

31.Hon, K. L.; Ching, G. K.; Leung, T. F.; Chow, C. M.; Lee, K. K.; Ng, P. C., Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults. J Dermatolog Treat 2009, 20 (3), 141-5.

32.Sumegi, A.; Szegedi, A.; Gal, M.; Hunyadi, J.; Szegedi, G.; Antal-Szalmas, P., Analysis of components of the CD14/TLR system on leukocytes of patients with atopic dermatitis. International archives of allergy and immunology 2007, 143 (3).

33.Ott, H.; Wilke, J.; Baron, J. M.; Hoger, P. H.; Folster-Holst, R., Soluble immune receptor serum levels are associated with age, but not with clinical phenotype or disease severity in childhood atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV 2010, 24 (4).

34.Muller, K. M.; Rocken, M.; Joel, D.; Bonnefoy, J. Y.; Saurat, J. H.; Hauser, C., Mononuclear cell-bound CD23 is elevated in both atopic dermatitis and psoriasis. J Dermatol Sci 1991, 2 (2), 125-33.

35.Kagi, M. K.; Joller-Jemelka, H.; Wuthrich, B., Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology (Basel, Switzerland) 1992, 185 (2).

36.Hatzistilianou, M.; Aggouridaki, C.; Catriu, D.; Athanassiadou, F., IL-4 and SCD23 in children with atopic dermatitis. European journal of pediatrics 1996, 155 (6).

37.Bottari, V.; Frezzolini, A.; Ruffelli, M.; Puddu, P.; Fontana, L.; De Pita, O., Cyclosporin A (CyA) reduces sCD30 serum levels in atopic dermatitis: a possible new immune intervention. Allergy 1999, 54 (5).

38.Cavagni, G.; Caffarelli, C.; Facchetti, F.; Brugnoni, D.; Notarangelo, L. D.; Tosoni, C.; Altobelli, R., Cutaneous CD30+ cells in children with atopic dermatitis. International archives of allergy and immunology 2000, 121 (3).

39.Miyagaki, T.; Sugaya, M.; Suga, H.; Morimura, S.; Kamata, M.; Ohmatsu, H.; Fujita, H.; Asano, Y.; Tada, Y.; Kadono, T.; Sato, S., Serum soluble CD26 levels: diagnostic efficiency for atopic dermatitis, cutaneous T-cell lymphoma and psoriasis in combination with serum thymus and activation-regulated chemokine levels. Journal of the European Academy of Dermatology and Venereology 2011, (Journal Article).

40.Bengtsson, A.; Holm, L.; Back, O.; Fransson, J.; Scheynius, A., Elevated serum levels of soluble CD30 in patients with atopic dermatitis (AD). Clinical and experimental immunology 1997, 109 (3).

41.Frezzolini, A.; Paradisi, M.; Ruffelli, M.; Cadoni, S.; De Pita, O., Soluble CD30 in pediatric patients with atopic dermatitis. Allergy 1997, 52 (1).

42.Caproni, M.; Bianchi, B.; D'Elios, M. M.; De Carli, M.; Amedei, A.; Fabbri, P., In vivo relevance of CD30 in atopic dermatitis. Allergy 1997, 52 (11).

43.Caproni, M.; Salvatore, E.; Cardinali, C.; Brazzini, B.; Fabbri, P., Soluble CD30 and cyclosporine in severe atopic dermatitis. International archives of allergy and immunology 2000, 121 (4).

44.Holm, L.; Bengtsson, A.; van Hage-Hamsten, M.; Ohman, S.; Scheynius, A., Effectiveness of occlusive bedding in the treatment of atopic dermatitis--a placebo-controlled trial of 12 months' duration. Allergy 2001, 56 (2).

45.Folster-Holst, R.; Henseler, T.; Wehde, J.; Lemke, H.; Weichenthal, M.; Christophers, E.; Hansen, H. P., Soluble CD30 plasma concentrations correlate with disease activity in patients with atopic dermatitis. Acta Dermato-Venereologica 2002, 82 (4).

46.Frezzolini, A.; Paradisi, M.; Zaffiro, A.; Provini, A.; Cadoni, S.; Ruffelli, M.; De Pita, O., Circulating interleukin 16 (IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): a novel serological marker of disease activity. Allergy 2002, 57 (9).

47.Di Lorenzo, G.; Gangemi, S.; Merendino, R. A.; Minciullo, P. L.; Cannavo, S. P.; Martinelli, N.; Mansueto, P.; Rini, G. B.; Corrocher, R.; Pacor, M. L., Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index. Mediators of inflammation 2003, 12 (2).

48.Heshmat, N. M.; El-Hadidi, E. S., Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2006, 17 (4).

49.Isolauri, E.; Arvola, T.; Sütas, Y.; Moilanen, E.; Salminen, S. Probiotics in the management of atopic eczema Clinical and Experimental Allergy [Online], 2000, p. 1604-10.

50.Noh, G.; Lozano, F. Intravenous immune globulin effects on serum-soluble CD5 levels in atopic dermatitis Clinical and Experimental Allergy [Online], 2001, p. 1932-8.

51.Kanbe, T.; Soma, Y.; Kawa, Y.; Kashima, M.; Mizoguchi, M., Serum levels of soluble stem cell factor and soluble KIT are elevated in patients with atopic dermatitis and correlate with the disease severity. The British journal of dermatology 2001, 144 (6).

52.Kakinuma, T.; Saeki, H.; Tsunemi, Y.; Fujita, H.; Asano, N.; Mitsui, H.; Tada, Y.; Wakugawa, M.; Watanabe, T.; Torii, H.; Komine, M.; Asahina, A.; Nakamura, K.; Tamaki, K., Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris. The Journal of allergy and clinical immunology 2003, 111 (3).

53.Hijnen, D.; De Bruin-Weller, M.; Oosting, B.; Lebre, C.; De Jong, E.; Bruijnzeel-Koomen, C.; Knol, E., Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. The Journal of allergy and clinical immunology 2004, 113 (2).

54.Hon, K. L.; Leung, T. F.; Ma, K. C.; Li, A. M.; Wong, Y.; Fok, T. F., Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children. Clinical and experimental dermatology 2004, 29 (3).

55.Hon, K. L.; Leung, T. F.; Wong, Y.; Lam, W. K.; Guan, D. Q.; Ma, K. C.; Sung, Y. T.; Fok, T. F.; Leung, P. C., A pentaherbs capsule as a treatment option for atopic dermatitis in children: an open-labeled case series. The American Journal of Chinese Medicine 2004, 32 (6).

56.Song, T. W.; Sohn, M. H.; Kim, E. S.; Kim, K. W.; Kim, K. E., Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2006, 36 (3).

57.Nakazato, J.; Kishida, M.; Kuroiwa, R.; Fujiwara, J.; Shimoda, M.; Shinomiya, N., Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2008, 19 (7).

58.Machura, E.; Rusek-Zychma, M.; Jachimowicz, M.; Wrzask, M.; Mazur, B.; Kasperska-Zajac, A., Serum TARC and CTACK concentrations in children with atopic dermatitis, allergic asthma, and urticaria. Pediatric Allergy and Immunology 2011, (Journal Article).

59.Paganelli, R.; Fanales-Belasio, E.; Carmini, D.; Scala, E.; Meglio, P.; Businco, L.; Aiuti, F., Serum eosinophil cationic protein in patients with atopic dermatitis. International archives of allergy and applied immunology 1991, 96 (2).

60.Czech, W.; Krutmann, J.; Schopf, E.; Kapp, A., Serum eosinophil cationic protein (ECP) is a sensitive measure for disease activity in atopic dermatitis. The British journal of dermatology 1992, 126 (4).

61.Krutmann, J.; Czech, W.; Diepgen, T.; Niedner, R.; Kapp, A.; Schopf, E., High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. Journal of the American Academy of Dermatology 1992, 26 (2 Pt 1).

62.Sugai, T.; Sakiyama, Y.; Matumoto, S., Eosinophil cationic protein in peripheral blood of pediatric patients with allergic diseases. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 1992, 22 (2).

63.Furue, M.; Sugiyama, H.; Tsukamoto, K.; Ohtake, N.; Tamaki, K., Serum soluble IL-2 receptor (sIL-2R) and eosinophil cationic protein (ECP) levels in atopic dermatitis. Journal of dermatological science 1994, 7 (2).

64.Kojima, T.; Ono, A.; Aoki, T.; Kameda-Hayashi, N.; Kobayashi, Y., Circulating ICAM-1 levels in children with atopic dermatitis. Annals of Allergy 1994, 73 (4).

65.Kato, K., Increased sensitivity of eosinophils for eosinophilopoietic cytokines in atopic dermatitis. The Kurume medical journal 1995, 42 (4).

66.Kowalzick, L.; Kleinheinz, A.; Weichenthal, M.; Neuber, K.; Kohler, I.; Grosch, J.; Lungwitz, G.; Seegeberg, C.; Ring, J., Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Dermato-Venereologica 1995, 75 (1).

67.Musial, J.; Milewski, M.; Undas, A.; Kopinski, P.; Duplaga, M.; Szczeklik, A., Interferon-gamma in the treatment of atopic dermatitis: influence on T-cell activation. Allergy 1995, 50 (6).

68.Nakama, T., Relationships between eosinophil-associated parameters and disease severity in atopic dermatitis. The Kurume medical journal 1995, 42 (2).

69.Halmerbauer, G.; Frischer, T.; Koller, D. Y., Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood. Allergy 1997, 52 (7).

70.Majamaa, H.; Isolauri, E., Probiotics: a novel approach in the management of food allergy. The Journal of allergy and clinical immunology 1997, 99 (2).

71.Krutmann, J.; Diepgen, T. L.; Luger, T. A.; Grabbe, S.; Meffert, H.; Sonnichsen, N.; Czech, W.; Kapp, A.; Stege, H.; Grewe, M.; Schopf, E., High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. Journal of the American Academy of Dermatology 1998, 38 (4).

72.Simon, D.; Weigl, L.; Disch, R., Influence of high-altitude climate therapy on atopic eczema. Allergologie 1999, 22 (6).

73.von Kobyletzki, G.; Pieck, C.; Hoxtermann, S.; Freitag, M.; Altmeyer, P., Circulating activation markers of severe atopic dermatitis following ultraviolet A1 cold light phototherapy: eosinophil cationic protein, soluble interleukin-2 receptor and soluble interleukin-4 receptor. The British journal of dermatology 1999, 140 (5).

74.Amon, U.; Memmel, U.; Stoll, R.; Amon, S., Comparison of severity scoring of atopic dermatitis values and serum levels of eosinophil cationic protein and mast cell tryptase for routine evaluation of atopic dermatitis. Acta Dermato-Venereologica 2000, 80 (4).

75.Gebhart, E.; Verdorfer, I.; Saul, W.; Trautmann, U.; Brecevic, L., Delimiting the use of comparative genomic hybridization in human myeloid neoplastic disorders. International journal of oncology 2000, 16 (6), 1099-105.

76.Huang, J. L.; Lee, W. Y.; Chen, L. C.; Kuo, M. L.; Hsieh, K. H., Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology 2000, 84 (3).

77.Pucci, N.; Lombardi, E.; Novembre, E.; Farina, S.; Bernardini, R.; Rossi, E.; Favilli, T.; Vierucci, A., Urinary eosinophil protein X and serum eosinophil cationic protein in infants and young children with atopic dermatitis: correlation with disease activity. The Journal of allergy and clinical immunology 2000, 105 (2 Pt 1).

78.Worm, M.; Ehlers, I.; Sterry, W.; Zuberbier, T., Clinical relevance of food additives in adult patients with atopic dermatitis. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2000, 30 (3).

79.Breuer, K.; Kapp, A.; Werfel, T., Urine eosinophil protein X (EPX) is an in vitro parameter of inflammation in atopic dermatitis of the adult age. Allergy 2001, 56 (8).

80.Capella, G. L.; Grigerio, E.; Altomare, G., A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. European journal of dermatology : EJD 2001, 11 (3).

81.Capoluongo, E.; Giglio, A. A.; Lavieri, M. M.; Lesnoni-La Parola, I.; Ferraro, C.; Cristaudo, A.; Belardi, M.; Leonetti, F.; Mastroianni, A.; Cambieri, A.; Amerio, P.; Ameglio, F., Genotypic and phenotypic characterization of Staphylococcus aureus strains isolated in subjects with atopic dermatitis. Higher prevalence of exfoliative B toxin production in lesional strains and correlation between the markers of disease intensity and colonization density. Journal of dermatological science 2001, 26 (2).

82.Gutgesell, C.; Heise, S.; Seubert, A.; Stichtenoth, D. O.; Frolich, J. C.; Neumann, C., Comparison of different activity parameters in atopic dermatitis: correlation with clinical scores. The British journal of dermatology 2002, 147 (5).

83.Petermann, F.; Gulyas, A. F.; Niebank, K.; Warschburger, P., Effects of Allergen Avoidance at High Altitude on Children with Asthma or Atopic Dermatitis. Pediatric Asthma, Allergy and Immunology 2004, 17 (1).

84.Angelova-Fischer, I.; Hipler, U. C.; Bauer, A.; Fluhr, J. W.; Tsankov, N.; Fischer, T. W.; Elsner, P., Significance of interleukin-16, macrophage-derived chemokine, eosinophil cationic protein and soluble E-selectin in reflecting disease activity of atopic dermatitis - From laboratory parameters to clinical scores. British Journal of Dermatology 2006, 154 (6).